绿叶制药利斯的明透皮贴剂获日本上市批准
3月31日，绿叶制药（02186）发布公告，宣布其自主研发的创新制剂利斯的明透皮贴剂（2次/W）已获得日本厚生劳动省的新药上市批准，用于抑制轻至中度阿尔茨海默病的进展。该产品在日本市场的商品名为Rivaluen®LAPatch 25.92mg/51.84mg，成为首款在日本获批的利斯的明缓释透皮贴剂。此次获批是基于在日本完成的临床试验的积极结果，试验已达到主要疗效终点。
为了加快该产品在日本的上市进程，公司于2020年12月与东和药品达成协议，授予其在日本市场独家开发及商业化的权利。东和药品是一家成立于1951年的知名制药公司，拥有丰富的商业运营经验和强大的运营体系。除了日本市场外，利斯的明透皮贴剂（2次/W）还已在欧洲多个国家和中国获批上市，并在东南亚和拉丁美洲的部分国家进行注册合作。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10